This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.Here is a sample of this item:Oncolytics releases Q3 results, continues Reolysin work 2009-11-05 15:18 ET - News Release Dr. Brad Thompson reports ONCOLYTICS BIOTECH(R) INC. ANNOUNCES 2009 THIRD QUARTER RESULTS Oncolytics Biotech Inc. has released its financial results for the three- and nine-month periods ended Sept. 30, 2009.
"In the third quarter, we passed a number of key milestones in our evolving Reolysin development program, including making progress on a number of phase II clinical initiatives and in manufacturing," said Dr. Brad Thompson, president and chief executive officer of Oncolytics. "Subsequent to quarter-end, we met our most important milestone to date in the advancement of our clinical program, as we reached an agreement with the U.S. FDA on the design of a phase 3 trial examining Reolysin in combination with paclitaxel and carboplatin, in patients with platinum-refractory head and neck cancers."
Selected third-quarter highlights:
During the quarter, the company announced: - Conclusion of patient enrolment in the phase II component of the
company's United Kingdom Reolysin and paclitaxel/carboplatin clinical trial
(REO 11);
- Successful completion of the lyophilized (freeze-dried) formulation
development program for Reolysin;
- Successful completion of an initial 100-litre production run of
Reolysin under cGMP conditions;
- The grant of the company's 32nd U.S. patent, No. 7,582,289, entitled
Viruses for the Treatment of Cellular Proliferative Disorders, with
the claims covering methods of using modified parapoxvirus orf virus
to treat Ras-mediated cancers;
- Acceleration of the warrant expiry date on warrants issued in
connection with a financing completed in December, 2008; and
- The start of enrolment in a U.S. phase 2 clinical trial, using
intravenous administration of Reolysin in combination with paclitaxel
and carboplatin, in patients with metastatic melanoma, being conducted
at the Cancer Therapy & Research Center at the University of Texas
Health Science Center (CTRC).
The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try,
click here for a free 30 day trial subscription. |
Top
Print this Page